Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KZR 
Kezar Life Sciences Inc (KZR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KZR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.65% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.95M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 29352 | Beta 0.49 | 52 Weeks Range 4.36 - 9.18 | Updated Date 04/1/2025 |
52 Weeks Range 4.36 - 9.18 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.49 |
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -2.76 | Actual -3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.45% | Return on Equity (TTM) -55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -83115840 | Price to Sales(TTM) 6.03 |
Enterprise Value -83115840 | Price to Sales(TTM) 6.03 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.06 | Shares Outstanding 7305800 | Shares Floating 4914027 |
Shares Outstanding 7305800 | Shares Floating 4914027 | ||
Percent Insiders 11.99 | Percent Institutions 61.95 |
Analyst Ratings
Rating 4 | Target Price 13.5 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kezar Life Sciences Inc
Company Overview
History and Background
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company founded in 2015, focused on discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The company went public in 2018.
Core Business Areas
- Protein Degradation: Kezar focuses on developing treatments that leverage protein degradation, particularly through the immunoproteasome, to modulate immune responses and address various diseases.
- Kezar Pipeline: Kezar Life Sciences is focused on developing treatments for autoimmune diseases and certain cancers.
Leadership and Structure
The leadership team includes experienced professionals in drug development and commercialization, including the CEO, CFO, and CSO. The company has a board of directors overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- Vespepcel: Vespepcel is being investigated for the treatment of systemic lupus erythematosus, dermatomyositis, and polymyositis. While there is no current revenue as Vespepcel is still in clinical trials. The competitors depend on disease but current treatments for Lupus include Benlysta, Saphnelo and others. Treatments for Dermatomyositis and Polymyositis include corticosteroids and immunosuppressants.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for immune-mediated disease therapies is growing due to increased prevalence and new therapeutic options.
Positioning
Kezar Life Sciences is positioned as a company focused on innovative small molecule therapeutics. Its competitive advantage lies in its targeted approach to protein degradation and unique pipeline targeting specific diseases.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapeutics is substantial, projected to reach hundreds of billions of dollars. Kezar is positioned to capture a share of this market if Vespepcel demonstrates efficacy and safety in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel Therapeutic Approach (Immunoproteasome Inhibition)
- Promising Clinical Trial Data
- Experienced Management Team
- Strong Intellectual Property Portfolio
Weaknesses
- Limited Product Portfolio (Reliance on Vespepcel)
- High R&D Costs
- Clinical Trial Risks
- No Currently Approved Products Generating Revenue
Opportunities
- Expansion of Pipeline through New Drug Candidates
- Partnerships and Collaborations with Larger Pharmaceutical Companies
- Potential for Breakthrough Therapy Designations
- Growing Market for Autoimmune Disease Treatments
Threats
- Clinical Trial Failures
- Competition from Established Pharmaceutical Companies
- Regulatory Hurdles
- Patent Challenges
Competitors and Market Share
Key Competitors
- BMY
- ABBV
- LLY
- MRK
- AMGN
- JNJ
Competitive Landscape
Kezar faces significant competition from established pharmaceutical companies with larger R&D budgets and broader product portfolios. Its advantage lies in its novel therapeutic approach, but it must demonstrate clinical efficacy and navigate regulatory challenges.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Kezar's growth has been primarily driven by clinical development milestones and pipeline expansion.
Future Projections: Future growth depends heavily on the success of Vespepcel in clinical trials and potential partnerships. Analyst estimates vary based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Vespepcel through clinical trials, exploring new indications, and preclinical studies
Summary
Kezar Life Sciences is a clinical-stage biopharmaceutical company with a novel approach to treating immune-mediated diseases. Its potential lies in the success of Vespepcel, but it faces challenges related to clinical trial risks and competition from larger pharmaceutical companies. The company's targeted therapeutic approach and experienced leadership offer potential for growth, but execution and market dynamics are crucial for its long-term success.
Similar Companies
- ARRY
- ALNY
- CRIS
- MRTX
- VRTX
- GILD
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated based on available public information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kezar Life Sciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-06-21 | Co-Founder, CEO & Director Dr. Christopher J. Kirk Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | |
Full time employees 55 | |||
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.